Company
Futura Medical PLC
LON:FUM
Futura Medical specialises in the development and global commercialisation of innovative sexual health products, including lead product Eroxon®. The company's core strength lies in its research, development and commercialisation of topically delivered gel formulations in sexual health products.
305 stories · page 5 of 16
Futura Medical erectile dysfunction gel in a strong position for FDA approval, says broker
On Monday, the company said it had submitted its regulatory dossier for MED3000
Futura Medical completes work ahead of FDA submission for ED gel
Eroxon is slated to become America's first over-the-counter treatment for erectile dysfunction
Futura Medical looks ahead to the launch of its breakthrough erectile dysfunction gel
“The whole team looks forward with growing excitement to the launch of Eroxon in the coming months,” said the company's chief executive James Barder
Futura Medical: Breakthrough gel has the potential to be America's first over-the-counter drug for erectile dysfunction
The assertion followed "highly positive" results from a US phase III clinical trial
Futura Medical set for another period of key news flow
Liberum said the US Food and Drug Administration could approve MED3000 in the first quarter of next year, unlocking a £250mln over-the-counter opportunity.
Futura Medical upgraded after Cooper Health deal
"Cooper Health appears a very credible PE-backed partner"
Futura Medical licenses ED treatment in Europe to Cooper
Futura will receive initial upfront payments as well as undisclosed cumulative sales milestone payments
Futura Medical a buy with data expected on "breakthrough" drug this year
MED3000 'works much faster than existing therapies, has a better side-effect profile and can be sold over the counter'
Futura Medical's latest deal underlines potential, says Liberum
Futura will receive an undisclosed up-front payment and will sell MED3000 to Menarini at a pre-agreed price.
Archive
Small Cap Wrap - Futura Medica, Aquis Exchange, Anglesea Mining, and more...
23 March 2022*A corporate client of Hybridan LLPDish of the dayJoiners:RC365 Holding has joined the Main Market (Standard). Founded in Hong Kong in 2013, the Group is a fintech solutions service provider in China and Hong Kong, and is looki
Futura Medical agrees South Korean licensing deal for erectile dysfunction gel
Menarini Group, a large Italian biopharma business, will also help garner marketing sign-off for MED3000